Prognoses of Advanced Esophago-gastric Junction Cancer May Be Modified by Thoracotomy and Splenectomy

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Feb 6

PMID 29399174

Citations 2

Authors

Kei Hosoda

Keishi Yamashita

Harukazu Tsuruta

Hiromitsu Moriya

Hiroaki Mieno

Akira Ema

Marie Washio

Masahiko Watanabe

Affiliations

Soon will be listed here.

Abstract

Globally, the incidence of esophago-gastric junction (EGJ) cancer is rapidly increasing. However, the proposed strategies for the treatment of these types of cancer are so diverse that there is no established consensus on the optimal treatment. The aim of the present study was to identify independent prognostic factors to delineate the optimal strategies for the treatment of EGJ cancer. The medical records of 150 patients with EGJ cancer who underwent curative surgery at the Kitasato University were retrospectively reviewed. The median follow-up period was 48 months. The patients with tumors that were classified as post-treatment primary tumor stage 3 [(y)pT3] or higher had a 5-year disease-specific survival (DSS) rate of 53%, whereas those with tumors that were classified as (y)pT0-2 had a 5-year DSS rate of 90%. Therefore, prognostic analysis was restricted to those tumors that were designated (y)pT3 or higher. A multivariate Cox's proportional hazards model identified the following independent prognostic factors that negatively influenced the DSS: i) Presence of tumors classified as post-treatment regional lymph node stage 1-3 [(y)pN1-3] [hazard ratio (HR), 3.62; 95% confidence interval (CI), 1.39-12.36]; ii) not undergoing treatment with splenectomy (HR, 2.40; 95% CI, 1.15-5.15); and iii) undergoing treatment with thoracotomy (HR, 2.07; 95% CI, 1.02-4.23). In patients with (y)pN0 tumors, the DSS rate was significantly improved for those who underwent splenectomy than for those who did not (P=0.024). In patients with (y)pN1-3 tumors, the DSS rate was significantly worse for those who underwent thoracotomy compared with those who did not (P=0.004). Splenectomy and thoracotomy may critically affect prognosis in locally advanced EGJ cancer that are classified as (y)pN0 and (y)pN1-3, respectively. Surgical treatments require optimization in order to improve prognoses in advanced EGJ cancer.

Citing Articles

Effect of two surgical approaches on the lung function and prognosis of patients with combined esophagogastric cancer.

Sun C, Han X, Wang H, Zhang Y, Wang M, Liu Y World J Gastrointest Surg. 2023; 15(9):1986-1994.

PMID: 37901732 PMC: 10600760. DOI: 10.4240/wjgs.v15.i9.1986.

A long-term survivor of recurrent esophagogastric junction adenocarcinoma treated with multidisciplinary therapy: a case report.

Tanaka T, Arigami T, Uenosono Y, Yanagita S, Matsushita D, Okubo K Surg Case Rep. 2020; 6(1):13.

PMID: 31919764 PMC: 6952476. DOI: 10.1186/s40792-020-0776-5.

References

Pohl H, Welch H . The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005; 97(2):142-6. DOI: 10.1093/jnci/dji024. View

Barbour A, Rizk N, Gonen M, Tang L, Bains M, Rusch V . Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg. 2007; 246(1):1-8. PMC: 1899203. DOI: 10.1097/01.sla.0000255563.65157.d2. View

Ui T, Fujii H, Hosoya Y, Nagase M, Mieno M, Mori M . Comparison of preoperative chemotherapy using docetaxel, cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagus. Dis Esophagus. 2014; 28(2):180-7. DOI: 10.1111/dote.12187. View

Korst R, Kansler A, Port J, Lee P, Kerem Y, Altorki N . Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma. Ann Thorac Surg. 2006; 82(2):480-4. DOI: 10.1016/j.athoracsur.2006.03.072. View

Blaser M, Saito D . Trends in reported adenocarcinomas of the oesophagus and gastric cardia in Japan. Eur J Gastroenterol Hepatol. 2002; 14(2):107-13. DOI: 10.1097/00042737-200202000-00003. View

Higashijima J, Shimada M, Chikakiyo M, Miyatani T, Yoshikawa K, Nishioka M . Effect of splenectomy on antitumor immune system in mice. Anticancer Res. 2009; 29(1):385-93. View

Noble F, Nolan L, Bateman A, Byrne J, Kelly J, Bailey I . Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. World J Gastroenterol. 2014; 19(48):9282-93. PMC: 3882401. DOI: 10.3748/wjg.v19.i48.9282. View

Takahashi H, Arimura Y, Yamashita K, Okahara S, Tanuma T, Kodaira J . Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol. 2009; 5(1):122-8. DOI: 10.1097/JTO.0b013e3181c1ffd5. View

Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T . Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. J Clin Oncol. 2003; 21(24):4592-6. DOI: 10.1200/JCO.2003.12.095. View

10.

Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M . S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008; 9(3):215-21. DOI: 10.1016/S1470-2045(08)70035-4. View

11.

Zanoni A, Verlato G, Giacopuzzi S, Weindelmayer J, Casella F, Pasini F . Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center. Ann Surg Oncol. 2013; 20(6):1993-9. DOI: 10.1245/s10434-012-2822-4. View

12.

Ng C, Wan I, Yim A . Impact of video-assisted thoracoscopic major lung resection on immune function. Asian Cardiovasc Thorac Ann. 2009; 17(4):426-32. DOI: 10.1177/0218492309338100. View

13.

Yamashita H, Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T . Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg. 2011; 254(2):274-80. DOI: 10.1097/SLA.0b013e3182263911. View

14.

Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H . A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2011; 19(1):68-74. DOI: 10.1245/s10434-011-2049-9. View

15.

Yamashita K, Sakuramoto S, Nemoto M, Shibata T, Mieno H, Katada N . Trend in gastric cancer: 35 years of surgical experience in Japan. World J Gastroenterol. 2011; 17(29):3390-7. PMC: 3160565. DOI: 10.3748/wjg.v17.i29.3390. View

16.

Sonoda K, Izumi K, Matsui Y, Inomata M, Shiraishi N, Kitano S . Decreased growth rate of lung metastatic lesions after splenectomy in mice. Eur Surg Res. 2006; 38(5):469-75. DOI: 10.1159/000095415. View

17.

Kusano C, Gotoda T, Khor C, Katai H, Kato H, Taniguchi H . Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol. 2009; 23(11):1662-5. DOI: 10.1111/j.1440-1746.2008.05572.x. View

18.

Tepper J, Krasna M, Niedzwiecki D, Hollis D, Reed C, Goldberg R . Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008; 26(7):1086-92. PMC: 5126644. DOI: 10.1200/JCO.2007.12.9593. View

19.

Goto H, Tokunaga M, Sugisawa N, Tanizawa Y, Bando E, Kawamura T . Value of splenectomy in patients with Siewert type II adenocarcinoma of the esophagogastric junction. Gastric Cancer. 2012; 16(4):590-5. DOI: 10.1007/s10120-012-0214-x. View

20.

Hirai T, Matsumoto H, Yamashita K, Urakami A, Iki K, Yamamura M . Surgical oncotaxis--excessive surgical stress and postoperative complications contribute to enhancing tumor metastasis, resulting in a poor prognosis for cancer patients. Ann Thorac Cardiovasc Surg. 2005; 11(1):4-6. View